Commentary on Chen et al. (2014): another step on the road to clinical utility of pharmacogenetics for smoking cessation?
Division of General Medical Disciplines, Stanford University School of Medicine, Stanford, CA, USA. spdavid@stanford.edu.
Sean P
SP
David
D016642:Bupropion / Q000627:therapeutic use*; D065637:Cytochrome P-450 CYP2A6 / Q000235:genetics*; D018765:Dopamine Uptake Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009538:Nicotine / Q000378:metabolism*; D012907:Smoking / Q000188:drug therapy*; D016540:Smoking Cessation / Q000379:methods*
D018765:Dopamine Uptake Inhibitors; D016642:Bupropion; D009538:Nicotine; C585710:CYP2A6 protein, human; D065637:Cytochrome P-450 CYP2A6
Bupropion; CHRNA5; CYP2A6; nicotine replacement; pharmacogenetics; smoking cessation